Doxorubicin stimulates transcription from the human immunodeficiency virus long terminal repeat sequences.
A recombinant plasmid carrying the long terminal repeat (LTR) of the human immunodeficiency virus 1 (HIV-1) linked to the reporter chloramphenicol acetyl transferase (CAT) gene was stably introduced into rat liver cells. The transfectant cells expressed CAT activity from the HIV LTR. The response to doxorubicin was studied and it was found that at the optimum concentration of 20 micrograms/ml doxorubicin, the expression of CAT from the HIV LTR was stimulated by 65-fold. Our results suggest caution against therapy including doxorubicin in the treatment of AIDS patients.
Zoumpourlis
V
V
Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Athens, Greece.
Kerr
D J
DJ
Spandidos
D A
DA
D000818:Animals; D001374:Azacitidine / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D015500:Chloramphenicol O-Acetyltransferase / Q000235:genetics / Q000378:metabolism; D004317:Doxorubicin / Q000494:pharmacology*; D016325:HIV Long Terminal Repeat / Q000187:drug effects*; D007700:Kinetics; D008099:Liver; D010957:Plasmids; D051381:Rats; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects*; D014162:Transfection
D011993:Recombinant Fusion Proteins; D004317:Doxorubicin; D015500:Chloramphenicol O-Acetyltransferase; D001374:Azacitidine